En español
NIDA

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

This study, building on the lessons learned from the ADAPT Study; will further investigate the effectiveness and safety of a combination pharmacotherapy (XR-NTX; as Vivitrol® plus once-daily bupropion extended-release tablets) for methamphetamine use disorder. 

CTN Protocol ID: 
CTN-0068
Enrollment Status: 
Pending
Principal Investigator(s)
Madhukar H. Trivedi, M.D.
Professor
University of Texas Southwestern Medical Center
Mood Disorders Research Program and Clinic
5325 Harry Hines Blvd, MC9119
Dallas, TX 75390
madhukar.trivedi@utsouthwestern.edu

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.